ArticleBMJ open2026
Screening for endometrial hyperplasia and endometrial cancer in premenopausal women with
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEndometrial hyperplasia (EH) is a condition that arises due to prolonged exposure of the endometrium to unopposed oestrogen, resulting in abnormal proliferation of endometrial tissue. Atypical hyperplasia, a subtype of EH, is considered a precursor lesion for endometrial cancer (EC). Polycystic ovary syndrome (PCOS) is a recognised risk factor for the development of EH and EC due to chronic anovulation and prolonged oestrogen exposure without progesterone opposition. Despite this increased risk, current clinical guidelines do not recommend routine screening for EH or EC among asymptomatic women with PCOS. The study aims to determine the effectiveness of screening for EH and EC in women with PCOS, particularly among premenopausal women, compared with no screening, reporting the occurrence and clinical outcomes of endometrial pathology among women with PCOS. METHODS AND ANALYSIS: This systematic review will adhere to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. A comprehensive literature search will be conducted across multiple electronic databases from inception until February 2026. Two reviewers will independently perform study screening, data extraction and methodological quality assessment of the included studies. Discrepancies between reviewers will be resolved through discussion or consultation with a third reviewer. Extracted data will be summarised narratively, and where appropriate, quantitative synthesis will be performed using Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI). Heterogeneity among studies will be assessed, and subgroup and sensitivity analyses will be conducted when feasible. ETHICS AND DISSEMINATION: Ethical approval is not required for this systematic review and meta-analysis, as it will use data from previously published studies. The results of the review will be published in academic journals and presented at international conferences. PROSPERO REGISTRATION NUMBER: CRD420251274598.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.